Parkinsonism

Researchers Identify Coffee Component That May Provide Neuroprotection

By November 08, 2018

The authors found that the compounds known as phenylindanes inhibited the aggregation of the amyloidgenic proteins beta-amyloid and tau.

Removing Appendix May Lower Risk for Parkinson's Disease

November 05, 2018

The researchers observed a correlation between removal of the appendix decades before PD onset and a lower risk for PD, especially for those living in rural areas.

Gocovri Treatment Effect Maintained for up to 2 Years in PD Patients With Dyskinesia

By October 09, 2018

The open-label safety study included patients from 3 Gocovri dyskinesia efficacy trials (N=223) and evaluated the long-term safety and tolerability of the treatment.

Do β2‐Adrenoreceptor Medications Affect Parkinson Disease Risk?

By October 05, 2018

In order to determine the risk of PD associated with various β2‐adrenoreceptor drugs, the study authors assessed United States Medicare beneficiary data from 2009.

High-Risk Anticholinergics Prescribed to Six Percent of Elderly

September 25, 2018

The researchers found that a high-risk anticholinergic prescription was listed for 6.2% of visits of older adults between 2006 and 2015, representative of 14.6 million total visits nationally.

FDA Issues Statement Addressing Safety Concerns Associated With Nuplazid

By September 21, 2018

Based on the data, the FDA has concluded that the drug's benefit continues to outweigh its risks for patients with hallucinations and delusions associated with Parkinson's disease psychosis.

Sensor Array May Detect De Novo Parkinson's Disease in Breath

August 27, 2018

The association with other common tests for PD diagnostics, including smell, ultrasound, and nonmotor symptoms, was also examined. Data were included for 29 PD patients after initial diagnosis and 19 control subjects.

FDA Approves New Nuplazid Formulation, Dosage Strength

By June 29, 2018

Nuplazid, a non-dopaminergic, selective serotonin inverse agonist, targets 5-HT2A receptors that are thought to be involved in Parkinson's disease psychosis.

Parkinson's Medications Tied to Impulse Control Disorders

June 21, 2018

The 5-year cumulative incidence of ICDs was 46.1% in 306 patients without ICDs at baseline (DA ever-users, 51.5%; DA never users, 12.4%).

Incidence of Extrapyramidal Symptoms Higher With Certain Antidepressants

By June 18, 2018

Within the cohort, 3838 cases were identified and compared with 38,380 age-matched controls.

FDA to Review Sublingual Tx for Motor Fluctuations in Parkinson's Disease

By June 13, 2018

The film is a new formulation of the dopamine agonist apomorphine, intended for rapid conversion from the OFF to the ON state; it has been studied to treat motor OFF episodes up to 5 times a day.

Primary Care Providers Have Mixed Views on Genetic Tests

May 14, 2018

They find tests for genetic risk potentially useful, but lack confidence in interpreting results

FDA Targets Clinics Offering Unapproved Stem Cell Therapies

May 11, 2018

The clinic claims its unapproved therapies can treat a number of serious diseases and conditions, including Parkinson's disease, amyotrophic lateral sclerosis (ALS), chronic obstructive pulmonary disease (COPD), heart disease, and pulmonary fibrosis.

Acadia Addresses Concerns Over Nuplazid Safety in Parkinson's Disease Patients

By April 27, 2018

Concerns over Nuplazid were initially voiced in a CNN article in early April which reported that the drug had been associated with over 700 deaths since its launch in March 2017.

Exposure to Anti-TNF Therapy Linked to Reduced Parkinson's Disease Risk

By April 24, 2018

Previous research has suggested a genetic and functional link between IBD and PD, however evidence regarding this association has been limited.

Long-Term Benefits of Gocovri Observed in PD Patients With Dyskinesia

By April 19, 2018

By 2 years, 30% of patients had increased their levodopa dose by ~300mg, indicating that treatment with Gocovri may allow for further levodopa optimization despite the occurrence of dyskinesia.

FDA-Approved App Allows Clinicians to Objectively Measure Balance

By April 18, 2018

The application assesses 3 key balance metrics: (1) double stance, (2) right tandem stance, and (3) left tandem stance.

Untrimmed Toenails: A Marker of Functional Status in Older Patients?

By April 13, 2018

For older patients, toenail length can provide important insight into a patient's functional status.

NDA Submitted for Sublingual Film to Treat OFF Episodes in Parkinson's Disease

By March 30, 2018

The NDA submission included data from Phase 3, 12-week, randomized, double-blind, placebo-controlled, parallel-group study (CTH-300) that enrolled patients with levodopa-responsive Parkinson's disease complicated by OFF episodes.

FDA to Review Xeomin for the Management of Excessive Drooling

By March 14, 2018

The sBLA is based on a Phase 3, randomized, double-blind, placebo-controlled, multicenter 184 subject trial.

Can Tears Be Used to Diagnose Parkinson's Disease?

February 23, 2018

The researchers observed a significant decrease in total alpha-synuclein in tears from PD patients relative to healthy controls (423.12 ± 52.6 versus 703.61 ± 136.4 pg/mg tear protein). PD patients also had significantly increased oligomeric alpha-synuclein relative to controls (1.45 ± 0.31 versus 0.27 ± 0.07ng/ng tear protein).

FDA Accepts NDA for Orally Inhaled Levodopa Therapy Inbrija

By February 21, 2018

Inbrija (previously known as CVT-301) is a self-administered, orally inhaled levodopa; it is designed to deliver a precise dose of a dry powder formulation of L-dopa to the lung.

Osmolex ER OK'd for Parkinson's Disease, Drug-Induced Extrapyramidal Reactions

By February 20, 2018

The approval of Osmolex ER was based on bioavailability studies comparing Osmolex ER to immediate-release amantadine.

Apomorphine Film Effectively Converts OFF to ON State in PD Patients

By January 30, 2018

The difference in score change for movement disorder from baseline to 30 minutes post-dose between the apomorphine and placebo group was 7.6 (P=0.0002).

Gocovri Now Available to Treat Dyskinesia in Parkinson's Disease Patients

By January 09, 2018

Gocovri is indicated for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications.

Caffeine Metabolism and Parkinson's Disease: What's the Link?

January 04, 2018

Significant decreases in serum levels of caffeine and nine of its metabolites seen in patients with early PD

Vercise Deep Brain Stimulation System Approved for Parkinson's Disease

By December 12, 2017

The FDA's approval was based on results from the 'Intrepid' study, the first multi-center, prospective, double-blind, randomized sham-controlled study of DBS for Parkinson's Disease in the U.S.

Anticholinergic Scoring Systems Appraised in Clinical Settings

November 28, 2017

The researchers found that the ACB showed the strongest and most consistent dose-response relationships with risks of all four adverse outcomes compared with ARS and DBI-Ach, especially among those aged 65 to 84 years.

Agranulocytosis Cases Prompt More Monitoring for Investigational Parkinson's Drug

By November 16, 2017

Dependent on further input from the Data Safety Monitoring Board (DSMB) and the Food and Drug Administration (FDA), the Company stated that they intend on moving forward with the study and expect to report results in the first quarter of 2018.

Sodium Oxybate Evaluated for Sleep-Wake Disturbances in PD Patients

November 08, 2017

Improvements in subjective sleep quality, objectively measured slow-wave sleep duration